DE602006012801D1 - Verwendung von 1- benzyl-1- hydroxy-2, 3-diamino-propylaminen, 3-benzyl-3 hydroxy-2-amino-propionsäureamiden und verwandten verbindungen als analgetika - Google Patents

Verwendung von 1- benzyl-1- hydroxy-2, 3-diamino-propylaminen, 3-benzyl-3 hydroxy-2-amino-propionsäureamiden und verwandten verbindungen als analgetika

Info

Publication number
DE602006012801D1
DE602006012801D1 DE602006012801T DE602006012801T DE602006012801D1 DE 602006012801 D1 DE602006012801 D1 DE 602006012801D1 DE 602006012801 T DE602006012801 T DE 602006012801T DE 602006012801 T DE602006012801 T DE 602006012801T DE 602006012801 D1 DE602006012801 D1 DE 602006012801D1
Authority
DE
Germany
Prior art keywords
benzyl
hydroxy
analgetics
propylamines
diamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006012801T
Other languages
English (en)
Inventor
Bertrand Leblond
Eric Beausoleil
Thierry Taverne
John E Donello
Fabien Jacques Schweighoffer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of DE602006012801D1 publication Critical patent/DE602006012801D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
DE602006012801T 2005-01-26 2006-01-25 Verwendung von 1- benzyl-1- hydroxy-2, 3-diamino-propylaminen, 3-benzyl-3 hydroxy-2-amino-propionsäureamiden und verwandten verbindungen als analgetika Active DE602006012801D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64727105P 2005-01-26 2005-01-26
PCT/US2006/002505 WO2006081252A2 (en) 2005-01-26 2006-01-25 Use of 1-benzyl-1-hydr0xy-2, 3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds as analgesics

Publications (1)

Publication Number Publication Date
DE602006012801D1 true DE602006012801D1 (de) 2010-04-22

Family

ID=36250723

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006012801T Active DE602006012801D1 (de) 2005-01-26 2006-01-25 Verwendung von 1- benzyl-1- hydroxy-2, 3-diamino-propylaminen, 3-benzyl-3 hydroxy-2-amino-propionsäureamiden und verwandten verbindungen als analgetika

Country Status (20)

Country Link
US (11) US8013000B2 (de)
EP (7) EP1841743B1 (de)
JP (6) JP5042040B2 (de)
KR (1) KR101395382B1 (de)
CN (2) CN101151248B (de)
AT (3) ATE549020T1 (de)
AU (4) AU2006209209B2 (de)
BR (5) BRPI0606112B8 (de)
CA (4) CA2595544C (de)
DE (1) DE602006012801D1 (de)
DK (3) DK1841756T3 (de)
ES (5) ES2436612T3 (de)
HK (2) HK1145628A1 (de)
HU (1) HUE028654T2 (de)
MX (1) MX2007008955A (de)
NZ (1) NZ556614A (de)
PL (2) PL383715A1 (de)
RU (1) RU2433999C2 (de)
WO (4) WO2006081280A1 (de)
ZA (1) ZA200706010B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8003617B2 (en) 2004-11-10 2011-08-23 Genzyme Corporation Methods of treating diabetes mellitus
JP5042040B2 (ja) 2005-01-26 2012-10-03 アラーガン、インコーポレイテッド 鎮痛活性および／または免疫賦活活性を有する１−アリール−１−ヒドロキシ−２，３−ジアミノ−プロピルアミン、１−ヘテロアリール−１−ヒドロキシ−２，３−ジアミノ−プロピルアミンおよび関連化合物
PT2032134E (pt) 2006-05-09 2015-10-07 Genzyme Corp Métodos de tratamento da doença do fígado gorduroso
WO2008011483A2 (en) * 2006-07-19 2008-01-24 Allergan, Inc. Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds
WO2008011485A2 (en) * 2006-07-19 2008-01-24 Allergan, Inc. Methods for treating chronic pain
WO2008011487A2 (en) * 2006-07-19 2008-01-24 Allergan, Inc. L-benzyl-l-hydr0xy-2, 3-diamin0-propyl amines and 3-benzyl-3-hydroxy-2-amino-propionicacid amides for chronic pain
WO2008011478A2 (en) * 2006-07-19 2008-01-24 Allergan, Inc. Methods for treating chronic pain using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
PT2481407T (pt) * 2007-03-06 2018-12-28 Allergan Inc Compostos para utilização no tratamento de distúrbios cognitivos
US8173683B2 (en) 2007-03-06 2012-05-08 Allergan, Inc. Methods for treating cognitive disorders
US20140179925A1 (en) 2009-09-04 2014-06-26 Allergan, Inc. Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
US9314466B2 (en) 2007-03-06 2016-04-19 Allergan, Inc. Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
CN101279955B (zh) * 2007-04-03 2012-11-28 北京摩力克科技有限公司 作为二肽肽激酶-iv抑制剂的n-取代硫吗啉衍生物及其医药用途
EP2594565B1 (de) 2007-05-31 2018-10-24 Genzyme Corporation Glukosylceramid-Synthase-Hemmer vom 2-Acylaminpropanol-Typ
EP2175850B1 (de) * 2007-07-17 2017-01-11 Allergan, Inc. Behandlung von angstzuständen
BRPI0823522A2 (pt) 2007-10-05 2014-01-07 Genzyme Corp Uso de um composto derivado de ceramida
US8168631B2 (en) 2008-02-05 2012-05-01 Allergan, Inc. 3-(4-fluorophenyl)-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic activity
WO2010014554A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
WO2010039256A1 (en) 2008-10-03 2010-04-08 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
KR101757003B1 (ko) 2009-07-17 2017-07-11 알러간, 인코포레이티드 인지 장애를 치료하기 위한 콜린에스테라아제 저해물질을 포함한 조성물
JP2013505247A (ja) * 2009-09-16 2013-02-14 アラーガン インコーポレイテッド 消化管運動障害を治療するための組成物および方法
AU2010295703A1 (en) * 2009-09-16 2012-04-12 Allergan, Inc. Compositions and methods for treating seizure disorders
EP2477622B1 (de) 2009-09-16 2014-08-20 Allergan, Inc. Pharmazeutische Zusammensetzung zur Behandlung von Spastizität
AU2010320963B2 (en) * 2009-11-18 2015-07-09 Fab Pharma Sas Novel heterocyclic acrylamides and their use as pharmaceuticals
HUE036381T2 (hu) 2013-08-15 2018-07-30 Allergan Inc (-)-(2R,3S)-2-amino-3-hidroxi-3-piridin-4-il-1-pirrolidin-1-il-propán-1-on (L)-(+) tartarát só, eljárás annak elõállítására és alkalmazása
EP3912977A1 (de) 2013-09-20 2021-11-24 BioMarin Pharmaceutical Inc. Glucosylceramid-synthase-inhibitoren zur behandlung von krankheiten
JP6152816B2 (ja) * 2014-03-26 2017-06-28 ソニー株式会社 半導体デバイス、表示パネル、表示装置、電子装置、および、半導体デバイスの製造方法
DE102015217629A1 (de) * 2015-09-15 2017-03-16 Tridonic Gmbh & Co Kg PFC-Modul für lückenden Betrieb

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2514380A (en) * 1946-12-26 1950-07-11 Hoffmann La Roche Diamines and method of production
DE1001261C2 (de) * 1954-08-05 1957-07-04 Thomae Gmbh Dr K Verfahren zur Herstellung von basischen Estern endocyclisch substituierter Mandelsaeuren und ihren Salzen
US2918466A (en) * 1955-05-24 1959-12-22 Univ St Johns Antimicrobial chemical compounds derived from alkoxyphenyl glycidic acid
US3065265A (en) * 1957-07-04 1962-11-20 Hoffmann La Roche Amino acid hydrazides
SU1063026A1 (ru) 1982-05-19 1990-12-07 Институт биохимии АН ЛитССР N @ -Бензолсульфонильные производные трес-DL-фенилсерина, обладающие противовоспалительной активностью
EP0144290A3 (de) * 1983-12-01 1987-05-27 Ciba-Geigy Ag Substituierte Aethylendiaminderivate
JPS60132935A (ja) 1983-12-20 1985-07-16 Sumitomo Chem Co Ltd フエニルセリン誘導体及びその製造方法
JPS61145148A (ja) 1984-12-19 1986-07-02 Sumitomo Seiyaku Kk フエニルセリン誘導体
GB8618188D0 (en) * 1986-07-25 1986-09-03 Ici Plc Diamine compounds
GB8622352D0 (en) * 1986-09-17 1986-10-22 Zambeleetti Spa Dr L Compounds
JPH02250845A (ja) 1989-03-22 1990-10-08 Sumitomo Pharmaceut Co Ltd ３―（４―フルオロフェニル）プロピオンアルデヒドの製造方法
EP0522606B1 (de) 1991-05-10 1996-04-03 Takeda Chemical Industries, Ltd. Pyridinderivate, deren Herstellung und Anwendung
JPH0550499A (ja) 1991-08-27 1993-03-02 Kuwabara Yasunaga 成形型内におけるトリミング方法及び容器
US6696486B1 (en) * 1992-01-22 2004-02-24 Glaxo Group Limited Medical use for atypical β-adrenoceptor agonists
CN1128951A (zh) 1993-08-13 1996-08-14 生化学工业株式会社 治疗神经元疾病的药物
JPH09506610A (ja) 1993-12-17 1997-06-30 ディーエスエム エヌ．ブイ． フェニルセリンアミド、及びフェニルセリン／フェニルセリンアミド の調製
AU698833B2 (en) * 1994-06-10 1998-11-12 Seikagaku Corporation 2-acylaminopropanol compound and medical composition
EP0782631A4 (de) 1994-09-19 1999-03-24 Univ Leland Stanford Junior Behandlung gegen plasmodium
US5585388A (en) * 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
FR2732894B1 (fr) 1995-04-13 1997-07-04 Sanofi Sa Nouvelle utilisation de composes agonistes beta9-adrenergiques
JPH08337569A (ja) * 1995-06-15 1996-12-24 Sankyo Co Ltd 鎮痛活性物質
WO2001004108A1 (en) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO1997010817A1 (en) * 1995-09-20 1997-03-27 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
NO965193L (no) * 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
JP3993908B2 (ja) * 1995-12-08 2007-10-17 生化学工業株式会社 アミノアルコール誘導体及び該誘導体の製造方法
DE19601745C1 (de) 1996-01-19 1997-10-09 Gruenenthal Gmbh Verfahren zur Racematspaltung von Tramadol
EP0848059A1 (de) * 1996-12-12 1998-06-17 Vetigen ICYP (Iodocyanopindolol) Rezeptor von Säugetieren und dessen Anwendungen
WO1998033501A1 (en) 1997-01-31 1998-08-06 Avid Therapeutics Inc. 2-benzoylamino-3-phenylpropenamide derivatives and methods of using the same
WO1998042657A1 (en) 1997-03-21 1998-10-01 The Scripps Research Institute SYNTHESIS OF α,β-SUBSTITUTED AMINO AMIDES, ESTERS AND ACIDS
JP4036500B2 (ja) 1997-05-23 2008-01-23 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
US6617340B1 (en) * 1999-07-29 2003-09-09 Novartis Ag N-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
SE9904197D0 (sv) 1999-11-22 1999-11-22 Amersham Pharm Biotech Ab A method for anion exchange adsorption on matrices carrying mixed mode ligands
US6407064B2 (en) 1999-12-06 2002-06-18 Seikagaku Corporation Aminoalcohol derivative and medicament comprising the same
US20030199571A1 (en) * 1999-12-24 2003-10-23 Gordon Bruton (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives
US6380398B2 (en) * 2000-01-04 2002-04-30 Novo Nordisk A/S Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
GB0010188D0 (en) * 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
KR20000063913A (ko) 2000-08-10 2000-11-06 하현준 아지리딘으로부터 1,2-디아미노프로판 알코올을 제조하는방법
WO2002062777A2 (en) 2001-01-10 2002-08-15 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20020198240A1 (en) * 2001-01-10 2002-12-26 Shayman James A. Amino ceramide - like compounds and therapeutic methods of use
ATE554082T1 (de) 2001-07-16 2012-05-15 Genzyme Corp N-acetylsphingosin glukosyltransferase inhibitor
WO2003013571A1 (en) * 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US6835831B2 (en) 2001-11-26 2004-12-28 Genzyme Corporation Diastereoselective synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
JP2006021997A (ja) 2002-07-09 2006-01-26 Ono Pharmaceut Co Ltd ｃｙｓＬＴ１／ｃｙｓＬＴ２両受容体拮抗性呼吸器疾患治療剤
US7309714B2 (en) * 2002-12-04 2007-12-18 Merck & Co., Inc. Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
KR101145252B1 (ko) 2003-01-08 2012-05-24 유니버시티 오브 워싱톤 항균제
JP4704914B2 (ja) * 2003-12-11 2011-06-22 田辺三菱製薬株式会社 α−アミノ酸誘導体及びその医薬用途
JP2007516294A (ja) * 2003-12-23 2007-06-21 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 炎症性の疾患または症状の予防および治療のための方法および組成物
US20070093492A1 (en) * 2004-03-09 2007-04-26 Weir-Torn Jiaang Pyrrolidine derivatives
EP1781331A1 (de) 2004-08-09 2007-05-09 Université Catholique de Louvain Verwendung von agonisten und antagonisten von beta-adrenozeptoren zur behandlung von arterienerkrankungen
DE102004053409A1 (de) 2004-11-05 2006-05-11 Bayer Healthcare Ag Verfahren zur gezielten Herstellung von Lysobactinfragmenten
JP5042040B2 (ja) * 2005-01-26 2012-10-03 アラーガン、インコーポレイテッド 鎮痛活性および／または免疫賦活活性を有する１−アリール−１−ヒドロキシ−２，３−ジアミノ−プロピルアミン、１−ヘテロアリール−１−ヒドロキシ−２，３−ジアミノ−プロピルアミンおよび関連化合物
US7858825B2 (en) * 2007-02-15 2010-12-28 Colorado State University Research Foundation Acid and base stable diphenylmethanol derivatives and methods of use
PT2481407T (pt) * 2007-03-06 2018-12-28 Allergan Inc Compostos para utilização no tratamento de distúrbios cognitivos
WO2008109286A1 (en) * 2007-03-06 2008-09-12 Allergan, Inc. Methods for treating cognitive disorders using 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds
US8173683B2 (en) * 2007-03-06 2012-05-08 Allergan, Inc. Methods for treating cognitive disorders
EP2175850B1 (de) * 2007-07-17 2017-01-11 Allergan, Inc. Behandlung von angstzuständen
US8168631B2 (en) 2008-02-05 2012-05-01 Allergan, Inc. 3-(4-fluorophenyl)-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic activity
AU2009249388B2 (en) * 2008-05-20 2014-04-03 Allergan, Inc. Therapeutic lactams
JP2013505247A (ja) * 2009-09-16 2013-02-14 アラーガン インコーポレイテッド 消化管運動障害を治療するための組成物および方法
EP2477622B1 (de) * 2009-09-16 2014-08-20 Allergan, Inc. Pharmazeutische Zusammensetzung zur Behandlung von Spastizität
AU2010295703A1 (en) * 2009-09-16 2012-04-12 Allergan, Inc. Compositions and methods for treating seizure disorders

Also Published As

Publication number Publication date
CA2595522A1 (en) 2006-08-03
US8153666B2 (en) 2012-04-10
BRPI0607379B1 (pt) 2020-06-30
US20120157497A1 (en) 2012-06-21
CN101151248B (zh) 2012-06-20
US8835463B2 (en) 2014-09-16
AU2006209197A1 (en) 2006-08-03
EP1841742A1 (de) 2007-10-10
DK1841423T3 (da) 2010-06-07
WO2006081273A8 (en) 2007-03-01
ATE549020T1 (de) 2012-03-15
EP1841423A2 (de) 2007-10-10
BRPI0606111B8 (pt) 2021-05-25
CN102718748B (zh) 2016-06-22
DK1841756T3 (da) 2011-10-17
BRPI0607379A2 (pt) 2009-09-01
JP5042040B2 (ja) 2012-10-03
ZA200706010B (en) 2009-04-29
NZ556614A (en) 2010-10-29
US9399628B2 (en) 2016-07-26
EP1841756B1 (de) 2011-09-07
JP5039564B2 (ja) 2012-10-03
JP2008528600A (ja) 2008-07-31
AU2006209208B2 (en) 2012-08-23
AU2006209207C1 (en) 2013-05-23
HK1145628A1 (en) 2011-04-29
AU2006209207B2 (en) 2012-08-23
JP2012162547A (ja) 2012-08-30
US20130310383A1 (en) 2013-11-21
EP2198864B1 (de) 2012-03-14
EP1841423B1 (de) 2010-03-10
US9828349B2 (en) 2017-11-28
US20090318499A1 (en) 2009-12-24
JP2008528602A (ja) 2008-07-31
US8513288B2 (en) 2013-08-20
EP1841743B1 (de) 2016-01-20
JP5107058B2 (ja) 2012-12-26
EP1841742B1 (de) 2013-10-30
AU2006209207A1 (en) 2006-08-03
HUE028654T2 (en) 2016-12-28
ES2380904T3 (es) 2012-05-21
CA2595519A1 (en) 2006-08-03
AU2006209208A1 (en) 2006-08-03
WO2006081280A1 (en) 2006-08-03
US20080312236A1 (en) 2008-12-18
PL1841743T3 (pl) 2016-06-30
US20120225881A1 (en) 2012-09-06
CA2595544C (en) 2013-04-02
EP2489658B1 (de) 2014-04-09
CA2595544A1 (en) 2006-08-03
JP2012162546A (ja) 2012-08-30
RU2433999C2 (ru) 2011-11-20
WO2006081252A3 (en) 2006-12-28
BRPI0606112A2 (pt) 2009-06-02
BRPI0607379B8 (pt) 2021-05-25
BRPI0606111A2 (pt) 2009-06-02
RU2007128313A (ru) 2009-03-10
CA2595522C (en) 2013-09-10
ES2565236T3 (es) 2016-04-01
AU2006209209A1 (en) 2006-08-03
BRPI0606112B8 (pt) 2021-05-25
BR122018068138B8 (pt) 2022-02-08
ES2436612T3 (es) 2014-01-03
HK1173721A1 (en) 2013-05-24
US9278943B2 (en) 2016-03-08
DK1841743T3 (en) 2016-03-14
BRPI0606112B1 (pt) 2021-02-23
US8288556B2 (en) 2012-10-16
US20160083371A1 (en) 2016-03-24
US8013000B2 (en) 2011-09-06
WO2006081276A1 (en) 2006-08-03
BRPI0607304A2 (pt) 2009-08-25
CN102718748A (zh) 2012-10-10
US20090088433A1 (en) 2009-04-02
ES2371265T3 (es) 2011-12-29
ATE523491T1 (de) 2011-09-15
US8927589B2 (en) 2015-01-06
PL383715A1 (pl) 2008-05-12
WO2006081276A8 (en) 2007-05-03
CA2595519C (en) 2013-10-29
EP2474534B1 (de) 2015-07-29
KR101395382B1 (ko) 2014-05-14
BR122018068138B1 (pt) 2021-09-08
US8431599B2 (en) 2013-04-30
US20090036436A1 (en) 2009-02-05
EP1841756A1 (de) 2007-10-10
CA2595542A1 (en) 2006-08-03
EP2198864A1 (de) 2010-06-23
EP1841743A1 (de) 2007-10-10
WO2006081273A1 (en) 2006-08-03
JP2008528596A (ja) 2008-07-31
ES2340196T3 (es) 2010-05-31
JP5042039B2 (ja) 2012-10-03
AU2006209209B2 (en) 2012-07-19
EP2489658A1 (de) 2012-08-22
US20130202653A1 (en) 2013-08-08
KR20070098946A (ko) 2007-10-05
MX2007008955A (es) 2007-09-18
WO2006081252A2 (en) 2006-08-03
US20130005717A1 (en) 2013-01-03
JP2008528601A (ja) 2008-07-31
CN101151248A (zh) 2008-03-26
BRPI0606111B1 (pt) 2020-12-15
US20110288094A1 (en) 2011-11-24
ATE460159T1 (de) 2010-03-15
EP2474534A1 (de) 2012-07-11

Similar Documents

Publication Publication Date Title
DE602006012801D1 (de) Verwendung von 1- benzyl-1- hydroxy-2, 3-diamino-propylaminen, 3-benzyl-3 hydroxy-2-amino-propionsäureamiden und verwandten verbindungen als analgetika
CY1111241T1 (el) Μεθοδος μειωσης α,β-ακορεστων κετονων σε οπιοεiδεις συνθεσεις
ATE430150T1 (de) 8-ä3-amino-piperidin-1-ylü-xanthine, deren herstellung und deren verwendung als dpp-iv hemmer
ATE528300T1 (de) Bizyklische verbindungen und ihre verwendung als antidiabetika
ATE542803T1 (de) Verfahren zur herstellung von dihydrochinazolinen
NO345046B1 (no) Oral doseringsform
BRPI0509660A (pt) compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias
ATE462701T1 (de) Verfahren zur herstellung von 4-(phenoxy-5-methyl-pyrimidin-4-yloxy)piperidin 1-carboxylsäure- derivaten und damit zusammenhängenden verbindungen
TW200700358A (en) Organic compounds
CY1112555T1 (el) Διεργασια χημικης συζευξης με ενα παραγωγο φαινυλ βορονικου οξεος
CY1113916T1 (el) Παραγωγα ετεροαρυλο πυρρολιδινυλο και πιπεριδινυλο κετονης
CO6382123A2 (es) Antagonistas de la via hedgehog de ftalazina disustituida
ATE498600T1 (de) Inden derivate als pharmazeutika
DE60312895D1 (de) Emulsionen mit oberflächenmodifizierten organischen molekülen
DE112008003640A5 (de) Verfahren zur Herstellung von 3,6-Dihydro-1,3,5-Triazin-Derivaten
BR0313588A (pt) Métodos para o tratamento da demência com base em apo e genótipo
TW200609226A (en) New isobenzoxazinones and their use as ultraviolet light absorbers
EA200901179A1 (ru) Замещённые тетрагидрохинолины
ATE371662T1 (de) Siliziumverbindungen und deren verwendung
ATE445592T1 (de) Derivate von heteroarylalkylcarbamaten, verfahren zu deren herstellung und deren verwendung als faah-enzyminhibitoren
ATE508130T1 (de) 3-oxa-10-aza-phenanthrene als pde4- oder pde3/4- inhibitoren
DE602007002716D1 (de) Neuroprotektive verbindungen und deren verwendungen
ATE374778T1 (de) Organosiliziumverbindungen und deren verwendung
BRPI0506996A (pt) compostos orgánicos
ATE547414T1 (de) 4-oxadiazolylpiperidinverbindungen und deren verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition